Now showing items 1-20 of 28

    • A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. 

      Kolinsky, MP; Rescigno, P; Bianchini, D; Zafeiriou, Z; Mehra, N; Mateo, J; Michalarea, V; Riisnaes, R; Crespo, M; Figueiredo, I; Miranda, S; Nava Rodrigues, D; Flohr, P; Tunariu, N; Banerji, U; Ruddle, R; Sharp, A; Welti, J; Lambros, M; Carreira, S; Raynaud, FI; Swales, KE; Plymate, S; Luo, J; Tovey, H; Porta, N; Slade, R; Leonard, L; Hall, E; de Bono, JS (2020-05)
      Background Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration-resistant prostate cancer (mCRPC). Recent evidence ...
    • Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. 

      Crespo, M; van Dalum, G; Ferraldeschi, R; Zafeiriou, Z; Sideris, S; Lorente, D; Bianchini, D; Rodrigues, DN; Riisnaes, R; Miranda, S; Figueiredo, I; Flohr, P; Nowakowska, K; de Bono, JS; Terstappen, LWMM; Attard, G (2015-03-31)
      Background Abiraterone and enzalutamide are novel endocrine treatments that abrogate androgen receptor (AR) signalling in castration-resistant prostate cancer (CRPC). Here, we developed a circulating tumour cells (CTCs)-based ...
    • BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. 

      Li, X; Baek, G; Ramanand, SG; Sharp, A; Gao, Y; Yuan, W; Welti, J; Rodrigues, DN; Dolling, D; Figueiredo, I; Sumanasuriya, S; Crespo, M; Aslam, A; Li, R; Yin, Y; Mukherjee, B; Kanchwala, M; Hughes, AM; Halsey, WS; Chiang, C-M; Xing, C; Raj, GV; Burma, S; de Bono, J; Mani, RS (2018-01)
      BRD4 belongs to the bromodomain and extraterminal (BET) family of chromatin reader proteins that bind acetylated histones and regulate gene expression. Pharmacological inhibition of BRD4 by BET inhibitors (BETi) has indicated ...
    • Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. 

      Lorente, D; Omlin, A; Zafeiriou, Z; Nava-Rodrigues, D; Pérez-López, R; Pezaro, C; Mehra, N; Sheridan, E; Figueiredo, I; Riisnaes, R; Miranda, S; Crespo, M; Flohr, P; Mateo, J; Altavilla, A; Ferraldeschi, R; Bianchini, D; Attard, G; Tunariu, N; de Bono, J (2016-12)
      Background The urgent need for castration-resistant prostate cancer molecular characterization to guide treatment has been constrained by the disease's predilection to metastasize primarily to bone. We hypothesized that ...
    • CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. 

      Shenoy, TR; Boysen, G; Wang, MY; Xu, QZ; Guo, W; Koh, FM; Wang, C; Zhang, LZ; Wang, Y; Gil, V; Aziz, S; Christova, R; Rodrigues, DN; Crespo, M; Rescigno, P; Tunariu, N; Riisnaes, R; Zafeiriou, Z; Flohr, P; Yuan, W; Knight, E; Swain, A; Ramalho-Santos, M; Xu, DY; de Bono, J; Wu, H (2017-07)
      Background Deletion of the chromatin remodeler chromodomain helicase DNA-binding protein 1 (CHD1) is a common genomic alteration found in human prostate cancers (PCas). CHD1 loss represents a distinct PCa subtype characterized ...
    • Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. 

      Goodall, J; Mateo, J; Yuan, W; Mossop, H; Porta, N; Miranda, S; Perez-Lopez, R; Dolling, D; Robinson, DR; Sandhu, S; Fowler, G; Ebbs, B; Flohr, P; Seed, G; Rodrigues, DN; Boysen, G; Bertan, C; Atkin, M; Clarke, M; Crespo, M; Figueiredo, I; Riisnaes, R; Sumanasuriya, S; Rescigno, P; Zafeiriou, Z; Sharp, A; Tunariu, N; Bianchini, D; Gillman, A; Lord, CJ; Hall, E; Chinnaiyan, AM; Carreira, S; de Bono, JS; TOPARP-A investigators (2017-09)
      Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity ...
    • Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients. 

      Nanou, A; Coumans, FAW; van Dalum, G; Zeune, LL; Dolling, D; Onstenk, W; Crespo, M; Fontes, MS; Rescigno, P; Fowler, G; Flohr, P; Brune, C; Sleijfer, S; de Bono, JS; Terstappen, LWMM (2018-04-10)
      The presence of Circulating Tumor Cells (CTCs) in Castration-Resistant Prostate Cancer (CRPC) patients is associated with poor prognosis. In this study, we evaluated the association of clinical outcome in 129 CRPC patients ...
    • Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. 

      Lorente, D; Olmos, D; Mateo, J; Dolling, D; Bianchini, D; Seed, G; Flohr, P; Crespo, M; Figueiredo, I; Miranda, S; Scher, HI; Terstappen, LWMM; de Bono, JS (2018-07)
      Background:The development of treatment response and surrogate biomarkers for advanced prostate cancer care is an unmet clinical need. Patients with baseline circulating tumour cell (BLCTCs) counts <5/7.5 mL represent a ...
    • Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. 

      Sharp, A; Welti, JC; Lambros, MBK; Dolling, D; Rodrigues, DN; Pope, L; Aversa, C; Figueiredo, I; Fraser, J; Ahmad, Z; Lu, C; Rescigno, P; Kolinsky, M; Bertan, C; Seed, G; Riisnaes, R; Miranda, S; Crespo, M; Pereira, R; Ferreira, A; Fowler, G; Ebbs, B; Flohr, P; Neeb, A; Bianchini, D; Petremolo, A; Sumanasuriya, S; Paschalis, A; Mateo, J; Tunariu, N; Yuan, W; Carreira, S; Plymate, SR; Luo, J; de Bono, JS (2019-11)
      Background Detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumour cells (CTCs) is associated with worse outcome in metastatic castration-resistant prostate cancer (mCRPC). However, studies rarely ...
    • Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. 

      Lorente, D; Olmos, D; Mateo, J; Bianchini, D; Seed, G; Fleisher, M; Danila, DC; Flohr, P; Crespo, M; Figueiredo, I; Miranda, S; Baeten, K; Molina, A; Kheoh, T; McCormack, R; Terstappen, LWMM; Scher, HI; de Bono, JS (2016-12)
      Background Treatment response biomarkers are urgently needed for castration-resistant prostate cancer (CRPC). Baseline and post-treatment circulating tumor cell (CTC) counts of ≥5 cells/7.5ml are associated with poor CRPC ...
    • Differential impact of RB status on E2F1 reprogramming in human cancer. 

      McNair, C; Xu, K; Mandigo, AC; Benelli, M; Leiby, B; Rodrigues, D; Lindberg, J; Gronberg, H; Crespo, M; De Laere, B; Dirix, L; Visakorpi, T; Li, F; Feng, FY; de Bono, J; Demichelis, F; Rubin, MA; Brown, M; Knudsen, KE (2018-01)
      The tumor suppressor protein retinoblastoma (RB) is mechanistically linked to suppression of transcription factor E2F1-mediated cell cycle regulation. For multiple tumor types, loss of RB function is associated with poor ...
    • EpCAM<sup>high</sup> and EpCAM<sup>low</sup> circulating tumor cells in metastatic prostate and breast cancer patients. 

      de Wit, S; Manicone, M; Rossi, E; Lampignano, R; Yang, L; Zill, B; Rengel-Puertas, A; Ouhlen, M; Crespo, M; Berghuis, AMS; Andree, KC; Vidotto, R; Trapp, EK; Tzschaschel, M; Colomba, E; Fowler, G; Flohr, P; Rescigno, P; Fontes, MS; Zamarchi, R; Fehm, T; Neubauer, H; Rack, B; Alunni-Fabbroni, M; Farace, F; De Bono, J; IJzerman, MJ; Terstappen, LWMM (2018-11-02)
      The presence of high expressing epithelial cell adhesion molecule (EpCAM high ) circulating tumor cells (CTC) enumerated by CellSearch ® in blood of cancer patients is strongly associated with poor prognosis. This raises ...
    • Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. 

      Seed, G; Yuan, W; Mateo, J; Carreira, S; Bertan, C; Lambros, M; Boysen, G; Ferraldeschi, R; Miranda, S; Figueiredo, I; Riisnaes, R; Crespo, M; Rodrigues, DN; Talevich, E; Robinson, DR; Kunju, LP; Wu, Y-M; Lonigro, R; Sandhu, S; Chinnaiyan, AM; de Bono, JS (2017-10)
      <b>Purpose:</b> Precise detection of copy number aberrations (CNA) from tumor biopsies is critically important to the treatment of metastatic prostate cancer. The use of targeted panel next-generation sequencing (NGS) is ...
    • HER-3 Expression and MEK Activation in Non-small Cell Lung Cancer 

      Manickavasagar, T; Yuan, W; Carreira, S; Gurel, B; Miranda, S; Ferreira, A; Crespo, M; Riisnaes, R; Baker, C; O’Brien, M; Bhosle, J; Popat, S; Banerji, U; Lopez, J; Bono, JD; Minchom, A
      Abstract BackgroundHER-3 has a role in pathogenesis and development of resistance to targeted therapies in non-small cell lung cancer (NSCLC). MethodsWe analysed tumour samples from 45 patients with adenocarcinoma of the ...
    • IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. 

      Calcinotto, A; Spataro, C; Zagato, E; Di Mitri, D; Gil, V; Crespo, M; De Bernardis, G; Losa, M; Mirenda, M; Pasquini, E; Rinaldi, A; Sumanasuriya, S; Lambros, MB; Neeb, A; Lucianò, R; Bravi, CA; Nava-Rodrigues, D; Dolling, D; Prayer-Galetti, T; Ferreira, A; Briganti, A; Esposito, A; Barry, S; Yuan, W; Sharp, A; de Bono, J; Alimonti, A (2018-07)
      Patients with prostate cancer frequently show resistance to androgen-deprivation therapy, a condition known as castration-resistant prostate cancer (CRPC). Acquiring a better understanding of the mechanisms that control ...
    • Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. 

      Nava Rodrigues, D; Rescigno, P; Liu, D; Yuan, W; Carreira, S; Lambros, MB; Seed, G; Mateo, J; Riisnaes, R; Mullane, S; Margolis, C; Miao, D; Miranda, S; Dolling, D; Clarke, M; Bertan, C; Crespo, M; Boysen, G; Ferreira, A; Sharp, A; Figueiredo, I; Keliher, D; Aldubayan, S; Burke, KP; Sumanasuriya, S; Fontes, MS; Bianchini, D; Zafeiriou, Z; Teixeira Mendes, LS; Mouw, K; Schweizer, MT; Pritchard, CC; Salipante, S; Taplin, M-E; Beltran, H; Rubin, MA; Cieslik, M; Robinson, D; Heath, E; Schultz, N; Armenia, J; Abida, W; Scher, H; Lord, C; D'Andrea, A; Sawyers, CL; Chinnaiyan, AM; Alimonti, A; Nelson, PS; Drake, CG; Van Allen, EM; de Bono, JS (2018-10)
      Background Understanding the integrated immunogenomic landscape of advanced prostate cancer (APC) could impact stratified treatment selection.Methods Defective mismatch repair (dMMR) status was determined by either loss ...
    • Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. 

      Minchom, A; Yuan, W; Crespo, M; Gurel, B; Figueiredo, I; Wotherspoon, A; Miranda, S; Riisnaes, R; Ferreira, A; Bertan, C; Pereira, R; Clarke, M; Baker, C; Ang, JE; Fotiadis, N; Tunariu, N; Carreira, S; Popat, S; O'Brien, M; Banerji, U; de Bono, J; Lopez, J (2020-03)
      Background This case represents an exceptional response to pembrolizumab in a patient with epithelioid mesothelioma with a further response on rechallenge.Case presentation A 77-year-old woman with advanced epithelioid ...
    • Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. 

      Mateo, J; Porta, N; Bianchini, D; McGovern, U; Elliott, T; Jones, R; Syndikus, I; Ralph, C; Jain, S; Varughese, M; Parikh, O; Crabb, S; Robinson, A; McLaren, D; Birtle, A; Tanguay, J; Miranda, S; Figueiredo, I; Seed, G; Bertan, C; Flohr, P; Ebbs, B; Rescigno, P; Fowler, G; Ferreira, A; Riisnaes, R; Pereira, R; Curcean, A; Chandler, R; Clarke, M; Gurel, B; Crespo, M; Nava Rodrigues, D; Sandhu, S; Espinasse, A; Chatfield, P; Tunariu, N; Yuan, W; Hall, E; Carreira, S; de Bono, JS (2020-01)
      Background Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and ...
    • Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. 

      Slovin, S; Hussain, S; Saad, F; Garcia, J; Picus, J; Ferraldeschi, R; Crespo, M; Flohr, P; Riisnaes, R; Lin, C; Keer, H; Oganesian, A; Workman, P; de Bono, J (2019-08)
      PURPOSE:Onalespib is a potent, fragment-derived second-generation HSP90 inhibitor with preclinical activity in castration-resistant prostate cancer (CPRC) models. This phase I/II trial evaluated onalespib in combination ...
    • Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. 

      McDaniel, AS; Ferraldeschi, R; Krupa, R; Landers, M; Graf, R; Louw, J; Jendrisak, A; Bales, N; Marrinucci, D; Zafeiriou, Z; Flohr, P; Sideris, S; Crespo, M; Figueiredo, I; Mateo, J; de Bono, JS; Dittamore, R; Tomlins, SA; Attard, G (2017-11)
      Objectives To use a non-biased assay for circulating tumour cells (CTCs) in patients with prostate cancer (PCa) in order to identify non-traditional CTC phenotypes potentially excluded by conventional detection methods ...